17.06.2011

Anti-apartheid activist Sisulu gets official funeral

Albertina Sisulu, a leading light of the former anti-apartheid movement and widow of an early mentor of Nelson Mandela, was given an official funeral on Saturday attended by South African government chiefs.

President Jacob Zuma and other top aides took part in the memorial service for Sisulu in a 40,000-seat football stadium in Soweto, the black township near Johannesburg synonymous with the fight against white-minority rule.

Top military generals carried the coffin of Sisulu, who died nine days ago at age 92, and the stadium was packed with mourners singing hymns.

A former nurse and community worker, Sisulu was a founding member of the African National Congress's Women's League where she served as deputy president during apartheid.

She was the widow of Walter Sisulu, who was one of Mandela's earliest mentors and was imprisoned with him for 25 years during the apartheid era that ended in the early 1990s.

Saturday's funeral was marked by personal tributes from family, friends and colleagues followed weeklong services and government tributes across the country.

"You are indeed one of the greatest South Africans," Mandela, who was South Africa's first post-apartheid, democratically elected president, said in a tribute to Sisulu read by his wife Graca Machel.

"I would have loved to be here today to pay my personal respects, but it would be too painful for me to see you go."

Sisulu was last seen in public when she visited Mandela, 92, in hospital in January.

Zuma said Sisulu's passing was an end of an era which had left the nation devastated. "Mama Sisulu suffered persecution, banning orders, imprisonment and harassment by the security apparatus of the apartheid regime, but she never compromised her beliefs," Zuma told mourners.

The Sisulu family retains a high profile in South Africa's political landscape -- daughter Lindiwe Sisulu is the defense minister and son Max Sisulu is a member of parliament.

(Editing by Mark Heinrich)

Chile ash cloud disrupts flights on two continents

A volcanic ash cloud originating in Chile delayed flights across South America and Australia, stranding thousands of travelers and forcing UN chief Ban Ki-moon onto an overnight bus.

The eruption of the Puyehue volcano, high in the Andes in southern Chile, entered a second week, spewing ash that has disrupted air travel on a scale unseen since the volcanic cloud over Iceland paralyzed Europe in 2010.

Buenos Aires airports suspended domestic and international flights on Sunday night for the third time in a week, prompting a crisis meeting Monday to assess the situation, the Argentine Civil Aviation Administration said.

"Meteorological conditions have worsened again, with forecasts that the cloud of volcanic ash will remain suspended in the area over the Ezeiza airport and the Jorge Newbery Metropolitan Airpark," the agency said.

At the Ezeiza international airport, an Ecuadoran tourist anxiously awaited a break in the dusk cloud to fly home for medical treatment.

"We're biting our nails, we're so anxious," she said.

Daniel Alegrin was stranded at the airport after flights to Alicante, Spain were delayed for a week.

"We come from Rosario (Argentina) and the (airline) refused to assume responsibility for our return home on grounds that it was a natural disaster," he said.

The UN secretary-general became the most high-profile person to be stranded after he was forced to rough it on an overnight bus to meet Argentinean leaders on Monday. Worse still -- it was his birthday.

All ended well as Ban, who marked his 67th birthday on Monday, made it to the capital in time to meet Argentinean leaders and win their support for a second term as secretary-general.

"We are very happy to welcome him and to say to him that we support with joy his re-election," said Argentine President Cristina Kirchner.

However aviation authorities in Buenos Aires re-opened the city's two main airports at 9 pm (0000 GMT Wednesday).

"The cloud of volcanic ash ... has diminished its intensity and reduced its impact, and the forecast is for the rest of (Monday) as well as the early hours of (Tuesday) it conditions will be favorable towards flying," the National Civil Aviation Association (ANAC) said in a statement.

Montevideo's Carrasco international airport in neighboring Uruguay however was still suspending operations, with more than 85 flights cancelled, officials said.

The flight disruption affected Peru's visiting president-elect Ollanta Humala, who canceled a late Monday dinner meal with Uruguay's President Jose Mujica and boarded a ship to Buenos Aires for the next leg of his trip. He had originally planned to leave Uruguay on Tuesday.

The Chilean Meteorological Service said prevailing winds would continue to blow the ash into Argentina through Wednesday.

Chilean seismologist Enrique Valdivieso said the eruption could run its course within a week, but it was hard to know based on precedent. An eruption in 1960 lasted two weeks, but an earlier one in 1921 lasted two months.

The June 4 eruption has been hardest for tourist areas near the volcano like the alpine resort of Bariloche, whose airport has been closed for a week, and Villa Angostura, which is 30 kilometers (18 miles) away.

Strong winds have carried the ash cloud half way around the world, snarling travel as far away as Australia.

Thousands of airline passengers faced a third day of delays in Australia on Tuesday as the ash cloud from Chile's volcanic eruptions continued to cause havoc.

Qantas and Jetstar have lifted a ban on flights to and from Melbourne but services by the two airlines in and out of the southern island of Tasmania and New Zealand remain grounded.

Flights to Adelaide by Qantas, Jetstar and Tiger were also grounded Tuesday with a review on the situation later expected in the day.

More than 110 Qantas flights were cancelled on Sunday and Monday, delaying at least 20,000 travellers while as many as 25,000 more passengers have been disrupted by Qantas's offshoot Jetstar suspending some flights.

The eruption in 2010 of an Icelandic volcano, Eyjafjoell, caused the biggest aerial shutdown in Europe since World War II, affecting more than 100,000 flights and eight million passengers.

Puyehue's eruption sent columns of debris 10,000 meters (six miles) high, blanketing the picturesque mountains and lakes along the Chile-Argentina border in a snowy white ash and prompting the evacuation of 3,500 people.

Its last major eruption was in 1960, following a 9.5 magnitude earthquake -- the largest on record.

Study of Vicor Technologies’ PD2i® Nonlinear Algorithm as Measure of Diabetic Autonomic Neuropathy Published in Clinical Neurophysiology

Nonlinear PD2i® heart rate complexity algorithm detects autonomic neuropathy in patients with type 1 diabetes mellitus,” authored by James Skinner, PhD, Vicor’s Vice President and Director of Research, in collaboration with Daniel Weiss, MD, Vicor’s Chief Medical Officer, and Jerry Anchin, PhD, Vicor’s Vice President and Director of Product Development,is included in the July 2011 (Volume 122 Number 7) edition of Clinical Neurophysiology.

Boca Raton, FL (PRWEB) June 16, 2011

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that a manuscript detailing a study of the ability of its PD2i Analyzer™ to detect the presence of autonomic neuropathy in individuals with type 1 diabetes mellitus is included in the July 2011 (Volume 122 Number 7) edition of Clinical Neurophysiology.Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

The manuscript, titled “Nonlinear PD2i® heart rate complexity algorithm detects autonomic neuropathy in patients with type 1 diabetes mellitus,” is authored by James Skinner, PhD, Vicor’s Vice President and Director of Research, in collaboration with Daniel Weiss, MD, Vicor’s Chief Medical Officer, and Jerry Anchin, PhD, Vicor’s Vice President and Director of Product Development.It details a study to test the ability of Vicor’s PD2i Analyzer™, which measures heart rate variability with a PD2i® nonlinear algorithm score, to detect early subclinical autonomic dysfunction in young (12.9-31.5 years)asymptomatic individuals with type 1 diabetes mellitus (DM).The study demonstrates the ability of the PD2i Analyzer™ to detect autonomic nervous system dysfunction very early in asymptomatic type 1 DM patients similar to the best discriminative power of previously published complexity measures.With a P value of 0.0006, the study results are highly statistically significant.

“We’re delighted to learn that Dr. Skinner’s manuscript, co-authored by our scientific and medical team members, has been included in the July 2011 edition of Clinical Neurophysiology.The clinical study on which this manuscript is based once again demonstrated the value of our PD2i Analyzer™ as a diagnostic that provides physicians with the ability to identify those at risk of future pathological events – in this case, diabetic autonomic neuropathy – that might otherwise remain unidentified and untreated, using traditional diagnostics.Most importantly, the PD2i Analyzer™ was able to identify those patients with early subclinical autonomic dysfunction with the results of a resting ECG.Absent the PD2i Analyzer™, the standard of care for diagnosing these patients with a measure of heart rate variability depends on ECGs taken during controlled exercise and paced respiration.Given its accuracy, ease of use, and minimal data requirements, the PD2i Analyzer™ appears destined to become a valuable clinical tool for the early detection of autonomic neuropathy in type 1 DM patients,” stated Mr. Fater.

Clinical Neurophysiology is the official journal of the International Federation of Clinical Neurophysiology.It is dedicated to fostering research and disseminating information on all aspects of clinical neurophysiology, both normal and abnormal. The journal aims at publishing scholarly reports on human physiology and pathophysiology of both the central and the peripheral nervous system.

About VicorTechnologies, Inc.Vicor Technologies’ PD2i Analyzer™ employs its patented, proprietary point correlation dimension algorithm (PD2i®), a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. Vicor anticipates use of its PD2i Analyzer™ to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at .

DisclaimerThe appearance of name-brand institutions, such as the International Federation of Clinical Neurophysiology, in this media release does not constitute endorsement by institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking StatementsForward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially.The following factors, among others, could cause our actual results to differ:our ability to successfully complete the normal range study for PD2i® values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain the necessary regulatory approvals to market the PD2i Analyzer™; our ability to develop additional applications for the PD2i Analyzer™; the ability of additional sales representatives to create revenue; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 11-16###

David H. FaterVicor Technologies, Inc.561.995.7313Email Information